Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass).</li>
<li>We will maintain our bullish view as long as market dynamics remain healthy and the SPX and ACWI-US are above 5700-5785 and $120-$121 (up from 5500 and $115).</li>
<li>We are upgrading Korea(KOSPI) to overweight; we discussed May 30 several Financials and other stocks to buy. KOSPI has exploded higher since, and is now reversing its 2-year RS downtrend.</li>
</ul>


We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass).
We will maintain our bullish view as long as market dynamics remain healthy and the SPX and ACWI-US are above 5700-5785 and $120-$121 (up from 5500 and $115).
We are upgrading Korea(KOSPI) to overweight; we discussed May 30 several Financials and other stocks to buy. KOSPI has exploded higher since, and is now reversing its 2-year RS downtrend.


Upgrading Korea to Overweight; MSCI ACWI and Emerging Market Breakouts

External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

<ul><li>SCHOTT Pharma AG &amp; Co. KGaA is experiencing accelerating growth in the pharmaceutical packaging industry due to the increasing prevalence of biologics, GLP-1s, and high value solutions.</li><li>The company's HVS segment is driving double-digit revenue growth and is expected to account for a larger percentage of total revenues in the future.</li><li>With solid pricing power in an oligopolistic industry, SCHOTT Pharma is well-positioned to benefit from the success of GLP-1s and further expand its market share.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

SCHOTT Pharma AG &amp; Co. KGaA is experiencing accelerating growth in the pharmaceutical packaging industry due to the increasing prevalence of biologics, GLP-1s, and high value solutions.The company's HVS segment is driving double-digit revenue growth and is expected to account for a larger percentage of total revenues in the future.With solid pricing power in an oligopolistic industry, SCHOTT Pharma is well-positioned to benefit from the success of GLP-1s and further expand its market share.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Schott Pharma Ag &Amp; Co. Kgaa  (1SXP GR) - Friday, Jan 26, 2024

Index Rebal Trades & Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal Trades & Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>In this insight, we take a look at the potential ADDs/DELs for the DAX index and the MDAX index in the run up to the June 2024 index rebal event.</li>
<li>I currently see no changes for the DAX index but there could be one change for the MDAX index.</li>
<li>M&amp;A candidate <a href="https://www.smartkarma.com/entities/morphosys-ag" target="_blank" data-smartkarma-citation="entities:21675:1" rel="noopener">MorphoSys AG (MOR GR)</a> could be deleted in the run up to the June 2024 review.</li>
</ul>


In this insight, we take a look at the potential ADDs/DELs for the DAX index and the MDAX index in the run up to the June 2024 index rebal event.
I currently see no changes for the DAX index but there could be one change for the MDAX index.
M&amp;A candidate MorphoSys AG (MOR GR) could be deleted in the run up to the June 2024 review.


Quiddity Leaderboard DAX/MDAX Mar 24: Traton Could Outperform the DAX Index

Germany

SCHOTT Pharma AG & Co. KGaA provides drug containment and drug delivery solutions. The Company offers prefillable syringes, cartridges, vials, and ampoules to analytical, development, fill-and-finish, and regulatory services for pharmaceutical companies, biotechs, and CDMOs. SCHOTT Pharma serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Schott Pharma (1SXP GR)

Upgrading Korea to Overweight; MSCI ACWI and Emerging Market Breakouts

MSCI $ACWI and Emerging Market $EEM Breakouts; Upgrading Korea $EWY to Overweight; Downgrading Broad Europe, but staying Overweight Germany,...

Vermilion Research

Schott Pharma Ag &Amp; Co. Kgaa (1SXP GR) - Friday, Jan 26, 2024

With solid pricing power in an oligopolistic industry, SCHOTT Pharma is well-positioned to benefit from the success of GLP-1s and further expand...

Value Investors Club (VIC)

Quiddity Leaderboard DAX/MDAX Mar 24: Traton Could Outperform the DAX Index

Commercial vehicle manufacturer Traton is a strong candidate for MDAX addition. The expected index flow could act as a catalyst and help the stock...

Janaghan Jeyakumar, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)